Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | NASDAQ:MRKR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 4.30% | 3.64 | 3.32 | 3.65 | 3.64 | 3.32 | 3.41 | 17,767 | 21:51:58 |
From Dec 2021 to Dec 2024
By Stephen Nakrosis
Shares of Marker Therapeutics Inc. jumped in after-hours trading Thursday, following news the U.S. Food and Drug Administration approved the company's investigational new drug application for MT-601 to treat certain patients with non-Hodgkin lymphoma.
At 5:54 p.m. ET, the company's shares were trading 100% higher at 66 cents a share. Volume in the after-hours market was over 2.4 million shares.
Peter L. Hoang, the company's president and chief executive, said, "FDA clearance of our IND for MT-601 is a significant milestone as we advance our pipeline in a number of company-sponsored trials." He added that MT-601 targets six tumor-associated antigens highly expressed in lymphoma, and said, "we look forward to initiating our company-sponsored Phase 1 study next year."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 04, 2022 18:13 ET (22:13 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Marker Therapeutics Chart |
1 Month Marker Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
